The involvement of?animal models in depression research

Animal models of depression allow scientists to investigate?the suspected biological, genetic, and environmental causes of depression, and to screen for drugs that will bring relief. Although there is no comparable model for human depression,?these animals may be informative for mechanisms and treatment.

Ace Therapeutics is committed to supporting scientists in making groundbreaking scientific discoveries and developing new applications to accelerate drug discovery and the scientific diagnosis and treatment of antipsychotic disorders. It has developed a range of animal models based on the etiology of depression, acute or chronic stress exposure, gene environment interaction, exogenous glucocorticoid administration, and gene manipulation. After being rigorously validated, these depression animal models including environmentally induced animal models, pharmacological animal models, and genetic animal models can mimic key aspects of human depression such as cognitive and behavioral deficits. With these models, researchers can not only examine the neural circuits in the controlled environment but also study the molecular and cellular pathways that may be crucial to the pathogenesis of depression.

In addition to animal modeling services for depression, Ace Therapeutics can also conduct depression behavior testing services to evaluate different components of depression in rodent models. For instance, the tail suspension and forced swim tests measure hopelessness, novelty-suppressed feeding measures apathy, and the sucrose preference test assesses anhedonia. Other tests to measure anxiety, including open field, elevated plus maze, and light/dark compartments, are also available at Ace Therapeutics. By incorporating these specialized depression-related behavior tests into its preclinical depression research services, Ace Therapeutics aims to refine the evaluation of potential therapeutic candidates.

Ace Therapeutics depression animal models coming with depression behavior testing services enable researchers to gather critical data and draw correlations between specific behaviors and potential pharmacological responses. Such advancements may help pharmaceutical partners develop more targeted and personalized treatments for those suffering from depression. Please see single photon emission computed tomography (SPECT) in psychiatry for more information.

About Ace Therapeutics

With a team of experienced researchers and state-of-the-art facilities, Ace Therapeutics strives to accelerate the development of innovative mental illness therapies. From basic research services to therapeutic development services, Ace Therapeutics offers tailored solutions to facilitate antipsychiatry studies, enabling the transformation of promising concepts into life-changing treatments.

Our behavioral testing system allows researchers to precisely measure functional recovery, which is important for validating neuroprotective and rehabilitative?therapeutics, explained the business development manager at Ace Therapeutics. Through incorporating these tests into pre-clinical research, we can narrow the gap between animal models and clinical?use.

Behavioral tests in rodent models of stroke are essential for evaluating functional deficits and assessing the efficacy of potential treatments. Some commonly used tests cover motor and sensorimotor tests (e.g., cylinder test, open field test, pole test, foot-fault test, corner test, adhesive removal test, rotarod test), cognitive & memory tests such as the Morris water maze, radial arm maze, Y-maze and elevated-plus maze. While there is no perfect test, there are a number of assessments that can be sensitive to detecting a range of impairments from overall to pattern-specific after stroke. And a combination of motor, sensory, and cognitive tests provides a comprehensive assessment of post-stroke deficits. The choice of tests depends on the research question and the specific deficits being investigated.

As an innovative stroke model behavioral assessment CRO focusing on early drug discovery from behavioral assessment and stroke model development, Ace Therapeutics offers a comprehensive suite of behavioral assays designed to measure motor, sensory, and cognitive impairments in rodent stroke models, including:

l Motor Function Tests: Beam walking, rotarod, and grip strength assessments to evaluate coordination and muscle function.

l Sensory-Motor Tests: Adhesive removal and foot fault tests to detect asymmetries and sensory deficits.

l Cognitive & Memory Tests: Morris water maze and novel object recognition to assess learning and memory impairments post-stroke.

Ace Therapeutics supports pharmaceutical companies, academic institutions, and biotech firms with customizable stroke research solutions, including custom endovascular filament models of middle cerebral artery occlusion (MCAO) and Endothelin-1 (ET-1) induced ischemic stroke models, hemorrhagic stroke models, and more. For researchers seeking to enhance their stroke studies with robust behavioral data, Ace Therapeutics offers expert guidance and validated protocols. Learn more about DAPK1 analysis in stroke.

About Ace Therapeutics

Ace Therapeutics is a leading provider of drug discovery and development services, specializing in the development of innovative therapies for stroke. With a focus on cutting-edge research and a commitment to excellence, Ace Therapeutics is dedicated to helping pharmaceutical companies complete their research programs faster and more successfully and finding effective therapies for stroke.